Composite resin reinforced with silk nanoparticles from Bombyx mori cocoon for dental applications

Abstract The objective of this work was to evaluate the mechanical performance of Z350 resin composite modified with Bombyx mori cocoons silk nanoparticles for dental applications. Four experimental groups were analyzed G0% = Filtek Z350 resin composite (control); G1% = Filtek Z350 with 1% of silk nanoparticles; G3% = Filtek Z350 with 3% of silk nanoparticles; G5% = Filtek Z350 with 5% of silk nanoparticles. It was employed scanning electron microscopy, energy dispersive X-ray spectroscopy, X-ray diffraction, 3-point flexural strength test, Knoop hardness test, and surface roughness. From 3-point flexural strength tests the control group presented the best results G0% = 113.33 MPa (±23.73). The higher flexural modulus was shown by groups G3% = 29.150 GPa (±5.191) and G5% = 34.101 GPa (±7.940), which are statistically similar. The Knoop microhardness test has shown statistical difference only among the G3% group between the top 80.78 (± 3.00) and bottom 68.80 (±3.62) and no difference between the groups. The roughness test presented no statistical difference between the groups. The incorporation of silk nanoparticles reduced the flexural strength of Z350 resin composite. The surface roughness and microhardness tests showed no changes in any of the groups studied.

Resumo O objetivo deste trabalho foi avaliar o desempenho mecânico da resina composta Z350 modificada com nanopartículas de seda Bombyx mori cocoons para aplicações odontológicas. Quatro grupos experimentais foram analisados: G0%) Resina Z350 apenas (grupo controle); G1%) Reforço com 1% de nanopartículas de seda; G3%) Reforço com 3% de nanopartículas de seda; e G5%) Reforço com 5% de nanopartículas de seda. Foi empregado microscopia eletrônica de varredura, espectroscopia de energia dispersiva de raios X, difração de raios X, teste de resistência à flexão de 3 pontos, teste de dureza Knoop e rugosidade superficial. Nos testes de resistência à flexão de 3 pontos o grupo controle apresentou melhores resultados G0% = 0.113 GPa (±0.024). O maior módulo de flexão foi demonstrado pelos grupos G3% = 29.151GPa (±5.191) e G5% = 34.102 GPa (±7.94), que são estatisticamente semelhantes. O teste de microdureza Knoop mostrou diferença estatística apenas entre o grupo G3% entre os 80.78 superiores (± 3.00) e os 68.80 inferiores (±3.62). Não há diferença entre os grupos. O teste de rugosidade não apresentou diferença estatística entre os grupos. A incorporação de nanopartículas de seda reduziu a resistência à flexão da resina composta Z350. Os testes de rugosidade superficial e microdureza não apresentaram alterações em nenhum dos grupos estudados.

Encapsulation of benznidazole in nanostructured lipid carriers and increased trypanocidal activity in a resistant Trypanosoma cruzi strain

Abstract Chagas disease is a neglected parasitic disease caused by Trypanosoma cruzi, whose treatment has remained unsatisfactory for over 50 years, given that it is limited to two drugs. Benznidazole (BZN) is an efficient antichagasic drug used as the first choice, although its poor water-solubility, irregular oral absorption, low efficacy in the chronic phase, and various associated adverse effects are limiting factors for treatment. Incorporating drugs with such characteristics into nanostructured lipid carriers (NLC) is a promising alternative to overcome these limiting obstacles, enhancing drug efficacy and bioavailability while reducing toxicity. Therefore, this study proposed NLC-BZN formulations in different compositions prepared by hot-melt homogenization followed by ultrasound, and the optimized formulation was characterized by FTIR, DRX, DSC, and thermogravimetry. Biological activities included in vitro membrane toxicity (red blood cells), fibroblast cell cytotoxicity, and trypanocidal activity against epimastigotes of the Colombian strain of T. cruzi. The optimized NLC-BZN had a small size (110 nm), negative zeta potential (-18.0 mV), and high encapsulation (1.64% of drug loading), as shown by infrared spectroscopy, X-ray diffraction, and thermal analysis. The NLC-BZN also promoted lower in vitro membrane toxicity (<3% hemolysis), and 50% cytotoxic concentration (CC50) for NLC-BZN in L929 fibroblast cells (110.7 µg/mL) was twice the value as the free BZN (51.3 µg/mL). Our findings showed that the NLC-BZN had higher trypanocidal activity than free BZN against the epimastigotes of the resistant Colombian strain, and this novel NLC-BZN formulation proved to be a promising tool in treating Chagas disease and considered suitable for oral and parenteral administration